|
A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma. |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Inventiva Pharma; Novocure; RS Oncology; targovax |
Consulting or Advisory Role - Bristol-Myers Squibb; Inventiva Pharma; Novocure; Roche; Targovax |
Speakers' Bureau - BMS; Boehringer Ingelheim |
Research Funding - Astex Pharmaceuticals; Bayer; Boehringer Ingelheim (Inst); Fuji Pharma (Inst); lab21 (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Amylyx (I); Apellis Pharmaceuticals (I); Biogen (I); Brainstorm Cell Therapeutics (I); Cytokinetics (I); GlaxoSmithKline (I); Lilly (I); Orion (I); Wave Pharmaceuticals (I) |
|
|
No Relationships to Disclose |